|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, February 16, 2017 ) Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021-Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
Diabetes mellitus is a group of metabolic diseases characterized by chronic hyperglycemia-high blood glucose levels-that results from defects in insulin secretion, insulin action, or a combination of these. This chronic hyperglycemia is associated with long-term damage, dysfunction and failure of multiple organs including the eyes, kidneys, nerves, heart and blood vessels. The vast majority of diabetes mellitus patients can be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2 Diabetes Mellitus (T2DM). Approximately 85-95% of all diabetics have T2DM.
For more information about this report: http://www.reportsweb.com/type-2-diabetes-mellitus-therapeutics-in-asia-pacific-markets-to-2021-increasing-usage-of-newer-therapies-and-expanding-treatment-population-to-encourage-robust-growth
T2DM treatment has been revolutionized in the past decade, especially with the increased use of new therapies. The marketed products landscape comprises a wide range of treatment options, including biguanide (metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonist, DPP-4 inhibitor, SGLT-2 inhibitor, and insulin therapies. Nevertheless, significant unmet need remains for products that can offer better glycemic control as well as the prevention and cure of diabetic complications, such as diabetic nephropathy, retinopathy, and cardiovascular disease.
Scope
The current T2DM in the Asia-Pacific (APAC) market contains novel products, including Jardiance-a SGLT-2 inhibitor; Victoza-a GLP-1 receptor agonist; and Galvus-a DPP-4 inhibitor.
-What are the competitive advantages of the existing novel drugs?
With over 500 active pipeline molecules, most of the late-stage investigational drug candidates are being evaluated, featuring improved dosing regimens and administration routes, in comparison to currently marketed products and combination therapies.
-Which classes of novel drugs are most prominent within the pipeline?
-Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis of clinical trials, since 2006, identified that the failure rates of T2DM molecules were highest in Phase II, at 54%, with the overall attrition rate for T2DM at 82.6%.
-How do failure rates vary by product stage of development, molecule type, and mechanism of action?
-How do other factors, such as average trial duration and trial size influence the costs and risks associated with product development?
Over the 2014-2021 forecast period, the T2DM therapeutics in the APAC markets is expected to increase in value at a CAGR of 7.7%, from $6.07 billion to over $10.2 billion.
-Which markets make the most significant contribution to the current market size?
-What are the epidemiology trends in these markets?
-Will new market entrants lead to substantial changes in annual therapy costs?
-How will different treatment usage patterns impact growth in the four assessed Asia-Pacific markets?
Rising T2DM prevalence and the uptake of newer therapies will lead to significant market growth, over the forecast period, despite generic sales erosion resulting from patent expirations.
-Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
-Which patent expirations will have the most significant impact on the market?
Request Sample Copy at http://www.reportsweb.com/inquiry&RW0001170041/sample
Reasons to buy
This report will enable you to-
-Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
-Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
-Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
-Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
-Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
-Compare treatment usage patterns, annual therapy costs, and market growth projections for China, India, Australia, and Japan.
-Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.
Table of Contents
1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 7
2 Introduction 9
2.1 Disease Overview 9
2.2 Classification 9
2.3 Symptoms 10
2.4 Etiology 10
2.5 Pathophysiology 11
2.6 Epidemiology 13
2.7 Prognosis 13
2.8 Co-morbidities and Complications 14
2.9 Diagnosis 15
2.10 Assessing Treatment Effectiveness 17
2.11 Treatment 17
2.11.1 Non-insulin T2DM Therapies 19
2.11.2 Insulin T2DM Therapies 22
2.12 Treatment Segments 24
2.12.1 Non-insulin therapies 24
2.12.2 Insulin Therapies 39
3 Marketed Products 43
3.1 Overview 43
3.2 Biguanides 44
3.2.1 Metformin 44
3.3 Sulfonylureas 45
3.4 Thiazolidinediones 47
3.4.1 Pioglitazone 47
3.5 GLP-1 receptor agonists 48
3.5.1 Byetta (exenatide) 48
3.5.2 Bydureon (exenatide) 49
3.5.3 Victoza (liraglutide) 50
3.5.4 Lyxumia (lixisenatide) 51
3.5.5 Tanzeum (albiglutide) 53
3.5.6 Trulicity (dulaglutide) 54
3.6 DPP-4 Inhibitors 55
3.6.1 Januvia/Glactiv (sitagliptin) 55
3.6.2 Galvus (vildagliptin) 56
3.6.3 Onglyza (saxagliptin) 57
3.6.4 Trazenta (linagliptin) 58
3.6.5 Zafatek (trelagliptin succinate) 59
3.6.6 Marizev (omarigliptin) 60
3.7 SGLT-2 Inhibitors 61
3.7.1 Forxiga (dapagliflozin) 61
3.7.2 Invokana (canagliflozin) 62
3.7.3 Jardiance (empagliflozin) 63
3.8 Insulin Therapies 63
3.8.1 Lantus (insulin glargine) 63
3.8.2 Levemir (insulin detemir) 64
3.8.3 Tresiba (insulin degludec) 65
3.8.4 Toujeo/ Lantus XR (insulin glargine) 66
3.9 Marketed Products Heat Maps 67
4 Pipeline 70
4.1 Overview 70
4.2 Pipeline Distribution by Stage of Development, Molecule Type and Program Type 71
4.3 Pipeline Distribution by Molecular Target 72
4.4 Clinical Trial Landscape 79
4.4.1 Clinical Trial Failure Rates 79
4.4.2 Clinical Trial Duration 84
4.4.3 Clinical Trial Size 87
4.4.4 Clinical Trial Metrics Analysis 90
4.5 Promising Pipeline Molecules 92
4.5.1 NN-9535 (subcutaneous semaglutide) and OG-217SC (oral semaglutide)-Novo Nordisk 92
4.5.2 ITCA 650-Intarcia Therapeutics 94
4.5.3 Ertugliflozin-Pfizer 96
4.6 Pipeline Products Heat Map 98
Inquire before Buying at http://www.reportsweb.com/inquiry&RW0001170041/buying
ReportsWeb.com
Priya Sisodia
+1-646-491-9876
sales@reportsweb.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
